UK-India Partnership for the control of FMD and PPR

Lead Research Organisation: The Pirbright Institute
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
 
Description 1. Collaboration between 4 Institutes in India for PPR work has been initiated
2.One new Institute is interested to initiate collaboration with Pirbright
3. Joint Publications have been made
4.Two BBSRC-DBT FADH project on FMD and PPR were successfully achieved.
Exploitation Route Two BBSR-DBT FADH grants and one follow on grant on PPR and FMD were funded. Under these research grants we have developed PPR DIVA vaccine and demonstrated how the duration of immunity can be increased for FMD vaccine and will help in the disease control programme.
Sectors Agriculture, Food and Drink,Education,Manufacturing, including Industrial Biotechology

 
Description Indian Immunologicals, an Industry ( manufacturer) for FMD and PPR vaccines became collaborator to the Pirbright Institute. Further recently working with indusrial partner we showed that TLR III adjuvant is capable of increasing the duration of immunity. Similarly in FADH project which was follow on to this partnering award helped us to develop PPR DIVA vaccines. All the results has been informed industries through FAO/OIE expert group/vaccine producers meeting.
Sector Agriculture, Food and Drink,Manufacturing, including Industrial Biotechology
 
Description Improvement on FMD and PPR vaccines. Through this partnering award we were able to achive further DBT-BBSRC FADH grant and BBSRC follow on grants whicvh helped us to improve the existing FMD and PPR vaccine. We have now demonstrated that adding TLR adjuvants to the existing vaccine the duration of immunity can be increased upto 6 months. Similarly we have develped PPR DIVA vaccine which can differentiate between infection and vaccination. The Indian Natioanl Goverment and industries are aware of this development so as other through recent FAO/OIE PPR meetings.
Geographic Reach Multiple continents/international 
Policy Influence Type Gave evidence to a government review
 
Description Longer duration immunity for FMD vaccine with TLR adjuvant-Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months.
Geographic Reach Multiple continents/international 
Policy Influence Type Gave evidence to a government review
 
Description An effective vaccination programme for the eradication of foot-and-mouth disease from India
Amount £673,500 (GBP)
Funding ID BB/L004828/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 11/2014 
End 02/2018
 
Description FADH PPR project -Understanding the immune mechanism of host disease resistance and development of marker vaccines and DIVA tests for Peste des Petits Ruminants (PPR)
Amount £351,000 (GBP)
Funding ID BB/L004801/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2014 
End 07/2018
 
Description Improving the duration of immunity for FMD vaccine
Amount £201,000 (GBP)
Funding ID BB/N012682/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 05/2016 
End 05/2017
 
Title Benifit of addition of TLR III to existing FMD vaccine 
Description We have demonstrated that TLR III adjuvants along with existing oil adjuvants provides longer duration immunity. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? No  
Impact This will fulfill the lacuna of short living immunity of FMD inactivated vaccines 
 
Title Use of reverse genetics to develop PPR DIVA vaccines 
Description Reverse genetics technique has been established for PPR virus in our laboratory. As PPR vaccine is a live attenuated virus, it is not possible to differentiate between vaccinated and infected animals (DIVA) in existing antibody assays. However using reverse genetics technique we have manipulated/mutated residues in the full-length cDNA of virus and rescued the live attenuated vaccine strain which worked as a DIVA vaccine. 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact PPR DIVA vaccine developed that can differentiate between vaccinated and infected animals. 
 
Description Adjuvants study-FMD vaccine at Indian Immunologicals 
Organisation Indian Immunologicals Ltd
Country India 
Sector Private 
PI Contribution Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months.
Collaborator Contribution Facilitate the animal experiments at their High containment
Impact Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months.
Start Year 2016
 
Description IVRI, Mukteswar 
Organisation Indian Veterinary Research Institute
Country India 
Sector Public 
PI Contribution 1. DIVA vaccine and DIVA test development. 2.Early pathogenesis study for PPR.3. Sharing of Knowledge 4.Joint publications
Collaborator Contribution Development LAMP technique for PPR
Impact 1. Development of DIVA vaccines and DIVA tests 2. Early pathogenesis study showed that PPR virus first replicates in Tonsils 3. LAM assay developed for PPR
Start Year 2014
 
Description Indian Veterinary Research Institute (IVRI), Bareilly 
Organisation Indian Veterinary Research Institute
Country India 
Sector Public 
PI Contribution 1. Development of PPR DIVA vaccine and DIVA tests 2. Early pathogenesis study
Collaborator Contribution Development of Biosensor diagnostic assay for PPR
Impact Joint publications. Sharing of knowledge.
Start Year 2014
 
Description NIAB, Hyderabad 
Organisation National Institute of Animal Biotechnology
PI Contribution DIVA vaccine and DIVA tests
Collaborator Contribution SNP study for disease resistance
Impact Development of DIVA vaccine and DIVA tests for PPR
Start Year 2014
 
Description PDFMD Mukteswar 
Organisation Indian Council of Agricultural Research
Department Foot and Mouth Disease Control Programme
PI Contribution Received 187 field viruses and antisera against existing vaccine viruses (O,A and ASia1). r1 value were obtained from 2D virus neutralisation assay. The joint publication has been made.
Collaborator Contribution Field sample provision
Impact Joint publications
Start Year 2012
 
Description TANUVAS, INdia 
Organisation Tamil Nadu Veterinary and Animal Sciences University
Country India 
Sector Academic/University 
PI Contribution 1. Development of DIVA vaccine and DIVA test. 2. Early pathogenesis study.3 Contributed to Transcriptome analysis carried out by TANUVAS
Collaborator Contribution Transcriptome study for disease resistance in different breed of goats, sheep and large ruminants
Impact 1.Development of DIVA vaccine.2. Development of DIVA tests 3. Early pathogenesis study showed that Virus first replicate in tonsils.4. High basal level of SLAM is present in large ruminants in comparison to small ruminants and may be therefore large ruminants are more resistant to the PPR.
Start Year 2014
 
Description Annual project meeting FADH PPR project at IVRI India- February 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The 3rd Annual project meeting for FADH project was carried forward at IVRI between project partners. The work progress has been discussed and further meetings at TANUVAS, India and Pirbright, UK are planned.
Year(s) Of Engagement Activity 2018
 
Description FMD workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Workshop on FMD control was conducted at PDFMD Mukteswar. Minimum 10 scientists from Pirbright and 10 from PDFMD had joined and delivered talks and discussed the FMD control. Agreement had been obtained to fr joint funding and publication and as shown further funding from DBT and BBSRC had been obtained.
Year(s) Of Engagement Activity 2014
 
Description Faculty talk at IVRI, India in PPR DIVA vaccine and DIVA tests development 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Satya Parida delivered an invited talk on PPR DIVA vaccine development using reverse genetics technique. Scientists and post graduate students were enjoyed the talk which sparked many questions and discussions afterwards and the joint Director of IVRI expressed interest on the work and further meetings.
Year(s) Of Engagement Activity 2018
 
Description Invited lead talk and Chairing brain sterming session on FMD vaccine and control at international conference at Hyderabad Organised by NIAB 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact 1.Invited lead talk on Epidemiology of PPR.2. Chairing brain sterming session on FMD vaccine and control at international conference on Infectious animal diseases at Hyderabad Organised by NIAB
Year(s) Of Engagement Activity 2014
 
Description Invited talk on Efficacy FMD vaccine using TLR adjuvants at NVRQS, South Korea 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Satya Parida was invited to deliver a talk on FMD vaccine using TLR adjuvants. Since 2010 South Korea is facing FMD outbreak and preparing themselves to prepare their own FMD Vaccine. As we have identified TLR 3 is a good adjuvant for stimulating humoral and cell-mediated response I received sparked questions and discussion afterwards. Recently I have received queries for providing details about the adjuvants so that they can include this adjuvant to their vaccine.
Year(s) Of Engagement Activity 2016
 
Description Invited talk on Epidemiology and vaccine development using reverse genetics techniques at Institute of Life science, Bhubaneswar India. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Invited talk on Epidemiology and vaccine development using reverse genetics techniques at Institute of Life science, Bhubaneswar India delivered on 5th of Feb, 2018. Students and scientists were encouraged to take forward the approach for human disease and some request obtained to visit our lab at the Pirbright, Institute.
Year(s) Of Engagement Activity 2018
 
Description Invited talk on new generation FMD vaccines at NIAB faculty 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Delivered an invited talk on new generation FMD vaccines to inform the collaborator how TLR III adjuvant lingers the duration of immunity. The talk initiated sparking questions after the talk.
Year(s) Of Engagement Activity 2017
 
Description Invited talk on reverse genetics to develp marker vaccine for FMD and PPR at OUAT, Bhubanesawar, India 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact Delivered a talk on development of viral vector vaccine for FMD and PPR and the same approach how could be adapted for other diseases.
Year(s) Of Engagement Activity 2016